RESEARCH ARTICLE

Immunogenicity and Protective Efficacy of *Brugia malayi* Heavy Chain Myosin as Homologous DNA, Protein and Heterologous DNA/Protein Prime Boost Vaccine in Rodent Model

Jyoti Gupta1,2, Manisha Pathak1, Sweta Misra1,2, Shailja Misra-Bhattacharya1,2*

1 Division of Parasitology, CSIR-Central Drug Research Institute, BS 10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow-226031, India, 2 Academy of scientific and Innovative Research, New Delhi, India

* shailja_cdri@rediffmail.com

Abstract

We earlier demonstrated the immunoprophylactic efficacy of recombinant heavy chain myosin (Bm-Myo) of *Brugia malayi* (*B. malayi*) in rodent models. In the current study, further attempts have been made to improve this efficacy by employing alternate approaches such as homologous DNA (pcD-Myo) and heterologous DNA/protein prime boost (pcD-Myo+Bm-Myo) in BALB/c mouse model. The gene *bm-myo* was cloned in a mammalian expression vector pcDNA 3.1(+) and protein expression was confirmed in mammalian Vero cell line. A significant degree of protection (79.2% ± 2.32) against L3 challenge in pcD-Myo+Bm-Myo immunized group was observed which was much higher than that exerted by Bm-Myo (66.6% ± 2.23) and pcD-Myo (41.6% ± 2.45). In the heterologous immunized group, the percentage of peritoneal leukocytes such as macrophages, neutrophils, B cells and T cells marginally increased and their population augmented further significantly following L3 challenge. pcD-Myo+Bm-Myo immunization elicited robust cellular and humoral immune responses as compared to pcD-Myo and Bm-Myo groups as evidenced by an increased accumulation of CD4+, CD8+ T cells and CD19+ B cells in the mouse spleen and activation of peritoneal macrophages. Though immunized animals produced antigen-specific IgG antibodies and isotypes, sera of mice receiving pcD-Myo+Bm-Myo or Bm-Myo developed much higher antibody levels than other groups and there was profound antibody-dependent cellular adhesion and cytotoxicity (ADCC) to *B. malayi* infective larvae (L3). pcD-Myo+Bm-Myo as well as Bm-Myo mice generated a mixed T helper cell phenotype as evidenced by the production of both pro-inflammatory (IL-2, IFN-γ) and anti-inflammatory (IL-4, IL-10) cytokines. Mice receiving pcD-Myo on contrary displayed a polarized pro-inflammatory immune response. The findings suggest that the priming of animals with DNA followed by protein booster generates heightened and mixed pro- and anti-inflammatory immune responses that are capable of providing high degree of protection against filarial larval invasion.
Introduction

Lymphatic filariasis (LF), a neglected tropical disease caused by *Wuchereria bancrofti*, *Brugia malayi* (*B. malayi*) and *B. timori* affects ~1.4 billion people globally. Annual single dose mass drug administration (MDA) program faces threat of drug resistance [1] as already indicated in veterinary helminthes [2,3]. Discovery of new antifilarial molecules or a potent vaccine is required to overcome this constraint. Filariids possess a complex life-cycle where each life-stage interacts through distinct host immunological channel. Some individuals exhibit an aggressive immune response with development of pathological symptoms while majority with detectable blood microfilariae (mf) remain apparently asymptomatic with dramatically elevated IgG4, IL-10, TGF-β, specific T cell hypo-responsiveness with impaired IFN-γ and IL-2 production that may facilitate parasite survival [4–5]. Endemic normal subjects in spite of being parasite and symptom free, mount a polarized Th1 response suggesting a Th1 effector mechanism based protective phenomenon.

Irradiated L3, recombinant proteins [6–8] and subunit vaccines [9–11] have been employed in the past to discover safe and effective vaccine against human filariids. We earlier identified a few prophylactic candidate antigens [7,12] including *B. malayi* recombinant myosin (Bm-Myo) which showed reactivity with endemic normal bancroftian serum [13,14]. Myosin, a body wall muscle protein has been probed as a vaccine candidate in other nematode parasites as well [15]. Myosin has been detected in the ES products after its release from the surface of parasite [16]. Immunization of rodents with a cocktail of Bm-Myo with another *B. malayi* recombinant protein (Bm-TPP) in our earlier study provided better protection over single protein via Th1/Th2 immunity [17].

DNA vaccines are third generation vaccines made up of a small, circular piece of bacterial DNA called plasmid which has been genetically engineered to produce one or two specific proteins (antigens) from a pathogen. DNA vaccine is the prime example of modern effective genetic immunization which entered human phase I and II trials in case of viral infections [18–23]. DNA vaccines are considered economic, they can be easily purified, protein remains in the native folded conformation and such vaccines have the advantage of inducing both humoral and cellular immune responses. Nevertheless, in vivo efficacy of genetic vaccines has not always been satisfactory. Several efforts have been employed to improve the efficacy of DNA vaccine such as codon/promoter optimization [24–26], use of adjuvants [27–28], formulations [29–30] and heterologous prime-boost regimes [31–32].

The heterologous DNA prime/protein boost vaccination strategy is an effective method that may overcome the shortcomings of DNA vaccination by utilizing the benefits of DNA and protein vaccines to effectively induce both cell-mediated immunity and antibody responses against invading organisms. Filarial Chitinase, paramyosin, GST, tropomyosin, ALT-2 and SXP-1 have successfully been employed as experimental DNA vaccine [33–36] against LF.

Attempts have been made in the current investigation to generate protective immune response employing Bm-Myo as DNA, DNA prime/protein-boost in BALB/c mice and their immun prophylactic efficacies have been compared with the purified recombinant myosin.

Materials and Methods

Animals

Male BALB/c mice (6–8 weeks old) were housed in our institute’s Laboratory Animal Facility, fed on standard pellet diet and water was provided *ad libitum* under pathogen free conditions.
Ethics statement
All the animals and experimental procedures were duly approved by the Animal Ethics Committee of CDRI duly constituted under the provisions of CPCSEA (Committee for the Purpose of Control and Supervision on Experiments on Animals), Government of India. The study bears approval no. IAEC/2011/145 dated 03/07/2012.

Plasmid construction
The *bm-myo* gene (accession number AY705730) was amplified using 1 μM each of gene specific forward 5’ GGATCCATGATGGATAATTCGGCACGAGAGTTC3’ and reverse 5’ CTCGAGAAACTGTACGCGTGAAGAAGAACGGAG3’ primers, 200 μM each dNTP (Fermentas, USA), 0.5 unit Taq DNA polymerase (Invitrogen, USA), 1xPCR buffer and 1.5 μM MgCl2 under the conditions of initial denaturation at 95°C/10 min, 29 cycles at 95°C/45 s, 62.3°C/1.30 min, 72°C/2 min and one cycle at 72°C/10 min. The amplified product (1924 bp) was cloned in the mammalian expression vector pcDNA 3.1(+) (Invitrogen) at Bam HI/XhoI restriction sites and transformed in competent *Escherichia coli* (E. coli) DH5α cells. The transformants were screened for the presence of recombinant plasmids having *bm-myo* insert by colony PCR after restriction digestion. Fidelity of the cloned product was verified by sequencing. The recombinant pcDNA3.1-bm-myo (pcD-Myo) construct was maintained and propagated in DH5α cells. Endotoxin-free plasmid DNA was isolated by Endo-free plasmid isolation kit (Qiagen, Germany) and used for *in vitro* transfection and immunization studies.

Transfection of plasmid constructs and Western blot
Vero cell line (Monkey kidney cells) was maintained in Minimal Essential Medium (MEM) (Invitrogen) fortified with antibiotic (penicillin 100 units/ml, streptomycin sulfate 100 μg/ml, neomycin mixture; Sigma, USA) and 10% Foetal bovine serum (FBS, Sigma). Vero cells were transfected with pcD-Myo construct using TurboFect transfection reagent (ThermoScientific, USA) following manufacturer’s protocol and protein expression was observed. Briefly, Vero cells were cultured in 24 well plates to produce 85–90% confluence before transfection. The diluted pcDNA3.1 vector and pcD-Myo construct (1 μg DNA each in 100 μl) were mixed with Turbofect (2 μl), incubated for 25 min at room temperature (RT) and the mixture was added drop wise to Vero cells under gentle rocking for transfection at RT for 45 min. Transfected cells were kept at 37°C in CO₂ incubator for 4–6 h and after 24 h, the medium was replaced with the fresh medium containing 400 μg/ml gentamycin (Sigma). Stably transfected Vero cell lysate was electrophoresed on 10% SDS-PAGE and transferred to PVDF membrane which was incubated with primary antibody (1:1000 anti-Bm-Myo) and subsequently with secondary antibody (1:10,000 HRP-goat anti-rabbit IgG; Sigma). Primary antibody was earlier raised in a male rabbit (1kg) by subcutaneous (s.c.) administration of three doses of 100 μg each of Bm-Myo emulsified in Freund’s Complete Adjuvant (FCA, Sigma) on day 0 followed by two booster doses of 100 μg each on days 15 and 30 in Freund’s Incomplete Adjuvant (FIA).

Expression and purification of recombinant protein
Bm-Myo cDNA clone was earlier picked up by immunoscreening of adult *female B. malayi* cDNA λuniZap expression library with human bancroftian serum pool and successfully cloned in pET28b expression vector, transformed in BL21 E. coli cells [14]. Transformants were grown in 10 ml Luria–Bertani (LB) medium containing 50 μg/ml of kanamycin overnight at 37°C. The overnight grown culture was inoculated in 500 ml of LB medium and further grown until A₆₀₀ reached ~0.6. The culture was induced with 0.5 mM isopropyl-d-thiogalactopyranoside (IPTG,
Sigma), re-incubated for another 3 h at 30°C to over-express the protein containing His tag at N-terminal. Induced cells were harvested, lysed in buffer A (50 mM NaH₂PO₄, 300 mM NaCl, pH 6.5) containing 10 mM imidazole and 1.0 mM phenylmethylene sulfonate fluoride (PMSF), sonicated and pelleted. The supernatant containing His-tagged Bm-Myo was passed through nickel nitriiotriacetic acid (Ni-NTA) affinity chromatography column. The column was washed with buffer A containing 10 mM, 20 mM or 50 mM imidazole and the recombinant myosin was eluted with 250 mM imidazole. Elutes were analyzed on 10% SDS-PAGE and fractions containing purified protein were pooled, dialyzed overnight against 50 mM NaH₂PO₄ at 4°C. The protein content was determined by the Bradford method [13]. The endotoxin levels were determined by the LAL Chromogenic Endotoxin Quantitation Kit (Thermoscientific) following manufacturer’s protocol.

**Immunization in mice and L3 challenge**

BALB/c mice were grouped as here under:

1. pcDNA (only vector)
2. Adjuvant control
3. pcD+Adjuvant control
4. pcD-Myo (recombinant plasmid construct)
5. Bm-Myo (recombinant myosin protein emulsified with adjuvant)
6. pcD-Myo+Bm-Myo (pcD-Myo plasmid construct and Bm-Myo as booster)

The immunization schedule is summarized in supplementary figures (S1 and S2 Figs). Sixty BALB/c mice (male, 18–22 g) were divided into 6 groups each containing 10 mice which were immunized on days 0, 15, 30 and 45. Control groups of mice (i, ii and iii) were injected with pcDNA (intradermally, i.d.), Adjuvant (FCA, FIA) (s.c.) or pcDNA+Adjuvant respectively. Group iv received 100 μg of pcD-Myo plasmid construct through i.d. route in 100 μl PBS (phosphate buffer saline pH 7.2). Group v received 25 μg of Bm-Myo+FCA (s.c.) on day 0 followed by three booster doses of Bm-Myo+FIA (s.c.) on days 15, 30 and 45. In the heterologous group vi, mice were primed with two i.d. injections of pcD-Myo construct on days 0 and 15 followed by two s.c. booster doses of Bm-Myo in adjuvant on days 30 and 45. On day 60, 5 mice from each group were randomly euthanized by intraval sodium (100 mg/kg) overdosing to measure the immune response including measurement of peritoneal exudate cell (PEC) population. Blood was collected for serum samples which were stored at —20°C for antibody measurement. The remaining 5 mice from each group were used for protection studies as described below as well as recruitment of various leukocytes in peritoneal cavity after L3 challenge. The experiment was repeated and the data is shown as mean±SE of two independent experiments using.

**Protection studies in BALB/c mice**

A week following the last booster, five remaining mice from each group were intraperitoneally (i.p.) challenged with ~50 B. malayi L3 recovered from experimentally infected laboratory bred mosquitoes (Aedes aegypti). Mice were euthanized on day 10 post challenge and their peritoneal cavities were washed to recover the developing parasites [37].

**Bm-Myo specific serum IgG**

IgG antibodies to Bm-Myo were determined in the mice sera by indirect ELISA [7]. Briefly, 96 well microtiter polystyrene plates (Nunc, Denmark) were coated with 1.0 μg/ml (100 μl/well)
of Bm-Myo, plates were blocked with 3.0% skimmed milk in PBS, incubated at 37°C with serial
two fold dilutions of primary antibody (serum from individual group of mice) and re-incu-
bated with secondary antibody (1:10,000 HRP-goat anti-mouse IgG). The antigen-antibody
reaction was detected after adding substrate OPD (o-phenyl diamine, Sigma) and the reaction
was stopped with 2.5 M H₂SO₄. Readings were taken at 492 nm in a multiplate reader (Infinite
Series M200, Tecan, Switzerland).

**Bm-Myo specific serum antibody isotypes**

Antibody isotypes were measured by ELISA using antibody isotyping kit (Sigma) as mentioned
earlier [7,13]. Wells were coated with 0.1 μg/ml of Bm-Myo, incubated with 1:1600 dilution of
primary antibody, re-incubated with isotype-specific monoclonal antibodies (1:1000 dilutions
of goat antimouse IgG1, IgG2a, IgG2b, IgG3, IgM and IgA) and subsequently with rabbit anti-
goat IgG-HRP (1:5000).

**Antibody-dependant cellular adhesion and cytotoxicity (ADCC) in vitro**

To determine the role of antibodies in larval killing, ADCC assay was performed as earlier
described [13]. Briefly, ~10 L3 each were co-cultured at 37°C with 0.5×10⁶ PECs from naive
BALB/c in triplicate in 96 well plate in presence of all groups of mice sera (optimized dilution
1:16) for 48 h and cell adherence and cytotoxicity to L3 observed. Cellular adherence was con-
sidered positive if >5 cells were attached to larval surface while limpid, damaged or immobile
L3 were considered as dead.

\[
\text{Percentage cytotoxicity} = \frac{\text{Number of dead larvae}}{\text{Total number of larvae}} \times 100
\]

**Isolation of PECs and Splenocytes**

PECs from all immunized and control groups after immunizations as well as post L3 challenge
were isolated in sterile ice cold PBS, using standard protocol. Briefly, small aliquot of PBS was
injected into the mouse peritoneum with the help of a needle attached to a syringe and gently
aspirated. The procedure was repeated until 8-10ml of peritoneal fluid was collected from each
mouse. Thereafter, peritoneal fluid was centrifuged at 300xg for 10 min at 4°C and pelleted
cells were washed twice with PBS and counted.

Spleens were aseptically removed, gently crushed, passed through a sterile nylon cell strainer
of 70 mm pore size (BD Biosciences, USA) to obtain single cell suspension and erythrocytes
were lysed with 0.84% chilled NH₄Cl solution, cells were washed and suspended in complete
RPMI (Sigma) [37].

**Reactive oxygen species (ROS)**

Oxidative burst was measured in PECs by incubating 1×10⁶ cells with 1 μM DCF-DA (2-
7-dichlorofluorescin diacetate, Sigma) for 15 min at 37°C in CO₂ incubator. The cells were
washed and ROS content was measured on FACS Calibur (BD Biosciences). Data was analyzed
by Flow Jo software (Tree star Inc., USA) and mean ROS values were evaluated [38].

**Differential leukocyte population in peritoneal lavage after immunization
and L3 challenge**

2x10⁶ PECs from immunized as well as L3 challenged mice were divided in separate tubes and
incubated with rat anti mouse monoclonal antibodies (BD biosciences) directed against CD3
(FITC; clone-45-2C11; T cell marker), CD19 (FITC; clone-1D3; B cell marker), Ly6C/G (PE-Cy7; clone-RB6-8C5; neutrophils marker), CD11c (PE-cy7 clone-HL-3 and singlec F (PE; clone-E50-2440; BD bioscience) as eosinophil markers and F4/80 (Pacific Blue; clone-BM8; invitrogen; macrophage marker). Cells were acquired on four or five-decade log-scale dot plots displaying forward scatter (FSC) area vs. side scatter area (SSC) after excluding the cell debris. Acquisition was carried out by FACS-Diva software on FACS Aria cell sorter (BD Biosciences) and analysis was performed using Flow Jo software (Tree star Inc., USA).

**Immunophenotyping of B cells and T cell subsets**

Splenocyte suspensions (1x10^6 cells) were probed with fluorochrome conjugated mouse monoclonal antibodies directed against CD4 (FITC; clone-H129.19), CD8 (phycoerythrin; clone 53–6.7) and CD19 (FITC; clone 1 D3) cell surface antigens following manufacturer’s protocol (BD Biosciences) as mentioned earlier [37]. Cells were incubated for 30 min at 4°C in dark, washed in PBS, suspended in FACS buffer and acquired on FACS after setting appropriate threshold voltages. A total of 20,000 events in the lymphocyte gate were acquired using BD cellquest software and data was analyzed by Flow Jo software (Tree star Inc.).

**Measurement of intracellular cytokines**

4x10^6 splenocytes were isolated and cultured with 5 μg of recombinant protein myosin for 12 h at 37°C in CO2 incubator followed by re-incubation with 10 μg/ml of Brefeldin A (BD Biosciences) in dark for 6 h at 37°C in CO2 incubator. Cells were washed and incubated with mouse seroblock FcR (BD Biosciences) for 10 min to block the non-specific binding of antibodies to CD16 and CD32 markers to curtail background signal. Cells were re-incubated in dark at 4°C overnight with FITC-CD4 antibody, washed with PBS, fixed and permeabilized for 15 min. Cell suspension was divided in separate tubes and incubated in presence of PE labelled anti-mouse monoclonal antibodies to IL-2, (clone-JES6-5H4), IL-4 (clone-BVD4-1D11), IFN-γ (clone-XMG1.2) and IL-10 (clone-JES5-16E3). Data was acquired on FACS Calibur and analyzed as above. PE labelled anti-mouse isotype control antibodies (IgG2b k for IL-2, IL-4, IL10 and IgG1 k for IFN-γ; BD Biosciences) were used as negative control.

**Statistical analysis**

The data were analyzed by PRISM software (version 5.0) using one-way analysis of variance (ANOVA). Two-way ANOVA was employed wherever required and individual comparisons were made by Bonferroni method. Probability values (P) of <0.05, <0.01, <0.001 between immunized and control groups were considered as significant (*), highly significant (**) and very highly significant (***) respectively.

**Results**

*bm-myo* gene was cloned in mammalian expression vector pcDNA3.1 (+) and transfected in Vero cell line with successful expression of protein

*bm-myo* gene was amplified from cDNA of adult *B. malayi* worms (Fig 1A), amplicon was cloned in the right frame of mammalian expression vector pcDNA3.1(+) and constructs were confirmed by restriction digestion (Fig 1B). Vero cells could be successfully transfected with pCD-Myo construct or vector pcDNA plasmid and protein expression was confirmed by Western blotting using rabbit anti-Bm-Myo antibody (Fig 1C). Sequencing confirmed no mutation demonstrating appropriately constructed recombinants expressed in mammalian cells.
Bm-Myo was overexpressed as single band

~73 KDa recombinant Bm-Myo protein was successfully over expressed at optimal IPTG induction and purified as a single band from E. coli pET28b-BL-21 (DE3) through Ni-NTA affinity column after elution with 250 mM imidazole. The endotoxin level of the purified protein preparation was found to be <0.1 EU/μg.

pcD-Myo+Bm-Myo conferred substantial protection against L3

Immunizations with pcD-Myo+Bm-Myo exhibited significant reduction (79.2%±2.32) in the recovery of developing larvae post L3 challenge as compared to Bm-Myo (P<0.01) and pcD-Myo (P<0.001). Bm-Myo and pcD-Myo led to 61.6%±2.23 and 41.6%±2.45 reductions in developing larvae recovered from mice on day 10 (Fig 2).

Bm-Myo generated high levels of serum IgG

pcD-Myo+Bm-Myo administered mice generated significantly higher titers of specific IgG antibodies at higher serum dilutions as compared to that of Bm-Myo group (P<0.001) (Fig 3) and at all dilutions with pcD-Myo immunized mice. Bm-Myo also triggered considerable IgG response (P<0.001) when comparison was made with pcD-Myo or other their respective control groups.

pcD-Myo+Bm-Myo elicited a mixed Th1/Th2 response with marginal Th2 skewing

All the three immunization schedules (pcD-Myo; Bm-Myo and pcD-Myo+Bm-Myo) led to generation of IgG1, IgG2a, IgG2b and IgG3 (P<0.001) (Fig 4A), however, pcD-Myo +Bm-Myo group of mice predominantly induced IgG1, IgG2a and IgG2b isotypes with IgG1: IgG2a ratio being >1 showing marginal bias towards Th2 immune response. Bm-Myo in contrast demonstrated a polarized Th1 response. Specific IgA and IgM were also elevated in
pcD-Myo+Bm-Myo (\(P<0.001\)) and Bm-Myo (\(P<0.001\)) group while pcD-Myo administered animals produced high levels of IgA (\(P<0.01\)) instead of IgM (Fig 4B).

Serum antibodies of pcD-Myo+Bm-Myo and Bm-Myo mice caused profound ADCC to L3

Serum of pcD-Myo+Bm-Myo and Bm-Myo mice promoted significant adherence of PECs to the surface of L3 causing 76.6\%±0.50 and 64.3\%±0.45 death of larvae within 48 h respectively in contrast to their respective controls (pcDNA+Adjuvant 20.0\%±0.58; Adjuvant 23.3\%±0.34). pcD-Myo or pcDNA did not show significant parasite killing (33.3±0.33\% and 16.3±0.30\% respectively) (Table 1, Fig 5).

Increased recruitment of differential leukocyte population in the peritoneal cavity of mice

The peritoneal leukocyte population in all immunized as well as control mice were assessed after immunization and also post-L3 challenge by FACS as described in material method section. No significant differences were observed as regards to the percentages of neutrophils and eosinophils after immunization in different groups. An increased population of B and T lymphocytes were observed in pcD-Myo+Bm-Myo over DNA and protein groups (\(P<0.01\) to...
while macrophages increased significantly ($P < 0.01$) in this group when it was compared with Myo-pcD group. The increase in B cells, T cells and macrophage population was noticed in Bm-Myo group but it was statistically significant only in comparison to control group ($P < 0.01$ to $P < 0.05$) (Fig 6A). However, L3 infection further enhanced the cellular recruitment including neutrophils in the peritoneal cavity of mice and the differences were significant ($P < 0.05$ to $P < 0.001$) in between the animal groups shown in Fig 6B, while a comparison of peritoneal cell population post-immunization and post-L3 challenge in individual group revealed significant difference only in Myo-pcD+Bm-Myo group although other groups demonstrated marginal increase in different cell populations (S1 Table).

**Oxidative burst**

Real-time monitoring of oxidative burst in the peritoneal cells containing major population of macrophages revealed significantly higher generation of reactive oxygen species (ROS) in all the three groups of immunized mice ($P < 0.001$), when compared with their respective controls (Fig 7A). However, pcD-Myo+Bm-Myo showed significant elevation in ROS generation as compared to pcD-myo but not in comparison to Bm-Myo.
Heterologous prime boost profoundly induced T and B cell population in mouse spleen

Fluorescent labeled monoclonal antibodies to cell surface antigens could identify the target cell population by their phenotypic markers. However, all the three vaccine formulations enhanced the expansion of CD4+, CD8+ T cells and B cell population in mouse spleen as compared to their respective controls. PcD-Myo+Bm-Myo mice revealed major increase as compared to Bm-Myo or Myo-pcD ($P<0.05$ to $<0.001$) ($\text{Fig } 7\text{B, }7\text{C and }7\text{D}$). The representative dot plots are appended in the $\text{Fig } 7\text{(a–l)}$.

Table 1. Antibody-dependent cellular adherence and cytotoxicity (ADCC) to L3 using sera of BALB/c mice immunized with different formulations. ADCC assay was performed by incubating pooled mice sera ($n=5$) samples with $0.5\times10^5$ normal PECs and $10^5 B.\malayi$ L3 at $37^\circ C$ for 48 h. Sera from animals in each group were pooled and used in duplicate for the assay. Statistical significance of the differences between mean values of immunized and control groups are shown as $* P<0.05$ and $*** P<0.001$. However, pcD-Myo+Bm-Myo showed significant difference over Bm-Myo ($*** P<0.001$) and pcD-Myo ($** P<0.01$) while Bm-Myo increased percent cytotoxicity significantly over pcD-Myo ($** P<0.01$), not shown in Table.

| Experimental group       | Percent cytotoxicity against L3       |
|--------------------------|---------------------------------------|
| pcDNA                    | 16.6±0.30                             |
| Adjuvant                 | 23.3±0.34                             |
| pcDNA +Adjuvant          | 20.0±0.58                             |
| Myo-pcD                  | 33.3±0.33*                            |
| Bm-Myo                   | 64.3±0.45***                          |
| Myo-pcD+Bm-Myo           | 76.6±0.50***                          |

* $P<0.05$, i.e., low significance;  
***$P<0.001$, very high significance
Production of both pro- and anti-inflammatory cytokines

Administration of pcD-Myo+Bm-Myo and Bm-Myo produced both pro-inflammatory (Th1) (IL-2, IFN-γ) (Fig 8A and 8B) and anti-inflammatory (Th2) (IL-4 and IL-10) cytokines (P<0.001) (Fig 9A and 9B) coinciding with an up-regulated CD4+ T lymphocyte population. PcD-Myo promoted enhanced production of IL-2, IFN-γ and IL-10 (P<0.001 to P<0.0), however, it had no significant effect on IL-4. The representative FACS dot plots are shown in Figs 8 (a–n) and 9(a–n) and data suggest that Bm-Myo provides significant Th1 and Th2 immune
Fig 6. Differential peritoneal leukocyte population measured by flowcytometry: (A) After immunization (B) After L3 challenge. $2 \times 10^6$ peritoneal cells from each group of mice ($n = 5$ in each group) were isolated by lavage and were stained for Ly6C/G, CD11c, singlecF, F4/80, CD3 as described in material method section and histogram represents percentages (mean±SE values) of different leukocytes as estimated by flow cytometry. Statistical significance between different groups is depicted as * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$. However, pcDNA, Adjuvant and pcDNA+adjuvant control groups did not show any noticeable change in various cell populations so only one representative control group (pcDNA) shown in figure.
doi:10.1371/journal.pone.0142548.g006

Fig 7. (A) Flowcytometric analysis of ROS generation by PECs. $(1 \times 10^6$/ml) cells isolated from all groups were loaded with probe DCFDA and ROS generation was evaluated. Values represent the mean fluorescence±SE. Flow cytometric analysis of T and B cells were carried out by staining of $1 \times 10^6$ cells with fluorescently labelled (B) CD4 (C) CD8 and (D) CD19 antibodies individually. Values represent the mean±SE from two separate experiments ($n = 5$ in each experiment). The differences in mean values were statistically analyzed and the comparison was done between all the immunized groups as well as their respective controls. The level of significance is depicted as * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$. Representative FACS dot plot of each group is shown in (a-l).
doi:10.1371/journal.pone.0142548.g007
Fig 8. Measurement of pro-inflammatory (Th1) cytokines in mice spleen. Flow cytometric analysis of intracellular Th1 (IL-2, IFN-γ) cytokine production in CD4+ T cells. Splenocytes were stained and processed as described in the material and method section. Bar graphs were generated for exhibiting percentage of CD4+ T cells positive for (A) IL-2 (B) IFN-γ. Values represent the mean±SE from two separate experiments. Statistical significance of the differences between all immunized groups and their respective control groups are shown as * P<0.05; ** P<0.01 and *** P<0.001. Their representative FACS dot plots are also shown in figure (a-n). Numbers in the upper-right quadrant of each dot plot represents the mean percentage of CD4+ T cells positive.
response in mice, however, CD4+ population producing these cytokines was much higher in the pcD-Myo+Bm-Myo group compared to other two regimens ($P<0.001$) suggesting their possible role in anti-larval protection.

**Discussion**

We earlier picked up Bm-Myo cDNA clone by immunoscreening of adult female *B. malayi* cDNA λAuniZap expression library and demonstrated its potential as an immunoprophylactic candidate antigen in single [13] as well as cocktail immunization with two other *B. malayi* recombinant proteins; independent phosphoglycerate mutase (Bm-iPGM) and trehalose-6-phosphate phosphatase (Bm-TPP) in rodent model [17]. An attempt has been made in the current investigation to elaborate on the potency of identified vaccine candidate (Bm-Myo) employing alternative immunization approaches such as homologous DNA and heterologous DNA prime/protein boost vaccination. DNA vaccination is one of the attractive approaches of vaccination that may able to facilitate expression of antigens that would be closer to native epitopes unlike recombinant proteins. The DNA vaccines remain poorly immunogenic compared to protein vaccines [39], however, new findings suggest that the prime-boost can be more immunogenic than the homologous vaccination and may elicit unique immune responses allowing for improved immunogenicity and protection against viral, bacterial, and parasitic infections [40–44].

In the current investigation, the pcD-Myo construct was successfully cloned in pcDNA 3.1 mammalian vector and expressed in Vero cell line and the immunogenicity and protective efficacy of pcD-Myo and pcD-Myo+Bm-Myo was evaluated in BALB/c mice and compared with homologous recombinant protein Bm-Myo. The protection studies against L3 challenge showed that pcD-Myo+Bm-Myo offered best protection (~79%) followed by Bm-Myo (~62%) unlike pcD-Myo (~42%) construct alone. Thus it becomes apparent that priming of mice with DNA construct needed further protein boosters to generate higher extent of protective efficacy. In heterologous prime boosts, the encoded antigen is delivered in a different form, which may facilitate focusing of the response on desired foreign antigen by minimizing distraction and antigenicity of the delivering vector [45]. Our results of humoral response showed that IgG antibody and IgG isotypes were remarkably much higher in mice immunized with pcD-Myo+Bm-Myo demonstrating that DNA priming followed by protein boosting achieved greater humoral immune responses than does either DNA or protein given separately [46–48]. There are sufficient evidences to show that IgG1, IgG2 and IgG3 antibodies provide adequate protection against LF in humans and mice [49–51]. Since all the three vaccinations up-regulated the production of both IgG1 and IgG2a isotypes indicating the production of mixed T helper cell response, However, the ratio of IgG1/IgG2a in each immunization group varied which was marginally biased towards Th1 type in Bm-Myo group as also mentioned earlier [13], while leaned towards Th2 in pcD-Myo+Bm-Myo administered group of mice. There are reports demonstrating production of humoral response predominantly of Th2-type after intradermal injection or topical application of immunogens [52]. Nevertheless, antigen-specific cytokine profile as observed by flow cytometry did not truly reflect this pattern and both Th1 and Th2 cytokines appeared equally elevated as also reported in other previous studies [53]. IgG1, IgG2a and IgM antibodies are suggested to be instrumental in killing of *B. malayi* L3 via ADCC mechanism, corresponding to this, our study demonstrated that pcD-Myo+Bm-Myo promoted adherence of PECs to the surface of L3 resulting in larval immobilization and death.
Fig 9. Measurement of anti-inflammatory (Th2) cytokines in mice spleen. Splenocytes were stained and processed as described in the material and method section and probed with fluorescently labelled monoclonal antibodies to IL-4 and IL-10 intracellular cytokines. Bar graphs were generated for exhibiting percentage of CD4+ T cells positive for (A) IL-4 and (B) IL-10. Values represent the mean±SE from two separate experiments. Statistical significance of the differences between mean values of all immunized as well as their respective control groups is shown as * P<0.05; ** P<0.01 and *** P<0.001 Representative FACS dot plots are shown in (a-n). PE labelled anti-mouse isotype control antibody (IgG1 k) was used a negative control to set quadrants.

doi:10.1371/journal.pone.0142548.g009
Not much information is although available on the role of IgA in protection against helminths though high IgA levels have been significantly correlated with the absence of filarial infection [54]. The immunized animals were challenged with *B. malayi* L3 in the peritoneal cavity and therefore differential leukocyte population in the peritoneal cavity of mice were analyzed which affirmed the crucial role of these cells in parasite clearance. The data revealed that Myo +Bm-Myo and Bm-Myo immunization up-regulated the percentage of macrophages, B and T lymphocytes which enhanced further significantly following L3 challenge. Neutrophils showed an increase especially after larval challenge suggesting their effective involvement in killing of larval parasites and indicated a complex interaction of these cells at the site of infection. Earlier reports also indicate that various cell population of peritoneum play a vital role in parasite killing and rapid accumulation of B cells and T cells is crucial to increase the number of macrophages and other cells that might have significant functional implications in the defense against *Brugia* infections [55–56]. There was only a marginal increase in the percentage of eosinophils in immunized mice post-L3 challenge in contrast to L3 infected control animals which demonstrated considerably increased infiltration of eosinophils suggesting that these cells are possibly not required for killing of the larvae in the adaptive immune response. This observation was also substantiated by earlier reports wherein it has been stated that a protective immune response utilizes different granulocytes in innate and adaptive protective immunity and eosinophils are required in the innate response i.e during a primary infection but not in adaptive response i.e secondary infection [57–59]. It was also noticed that pcD-Myo preferentially induced rapid expansion of CD8+T cells while Bm-Myo and pcD-Myo+Bm-Myo prime boost considerably up-regulated both CD4 + and CD8+ T cells along with B cell population. The production of pro-inflammatory (IL-2, IFN-γ) and anti-inflammatory (IL-4, IL-10) cytokines was highest in pcD-Myo+Bm-Myo vaccination showing a robust mixed Th1/Th2 type of immune response. Studies undertaken earlier by other workers [60–61] have demonstrated natural killer cell (NKT) activation by intradermal DNA priming as well as dendritic cell maturation leading to enhanced CD4 and CD8 T cell effector response and both these responses have been demonstrated to be important for the control of filariasis. The above reports substantiate our findings where pcD-Myo primed antigen specific T-cells and then induced a rapid T-cell expansion with repeated antigen leading to finer protection by pcD-Myo+Bm-Myo vaccination group which illustrated more robust immune response than the pcD-Myo group.

Thus, it may be concluded that the current efforts to improve the efficacy of the Bm-Myo using alternative prime boost approach was successful. The data also revealed that the response elicited by homologous DNA vaccine was not as efficient as the recombinant myosin protein, however, DNA prime+protein-boost vaccination generated both humoral and cellular immune responses against *B. malayi* L3 unlike other immunization protocols which was capable of providing ~79% protection to BALB/c mice against challenged L3. The heterologous prime boost method of vaccination is therefore being advocated as a promising means of immunization against LF.

**Supporting Information**

S1 Fig. Schematic representation of (a) homologous DNA vaccination (pcD-Myo); (b) protein vaccination (Bm-Myo) and (c) heterologous prime boost regimen (pcD-Myo+Bm-Myo) in BALB/c mice. Animals in the DNA vaccination group received 100 μg pcD-Myo construct alone intradermally; in protein vaccination regimen mice received 25μg Bm-Myo with FCA subcutaneously and boosted with Bm-Myo emulsified in FIA, in heterologous prime
boost regimen mice were primed with 100 μg pcD-Myo construct intradermally and two times boosted with 25μg Bm-Myo+FIA. *Immunized Intradermally; †Immunized subcutaneously.

(TIF)

S2 Fig. Schematic representation of control mice immunized with different preparations. i) control group for pcD-Myo group; ii) Adjuvant group as control against Bm-Myo group; iii) mice immunized with vector pcDNA+Adjuvant as control group against pcD-Myo+BmMyo * Immunized Intradermally; †Immunized subcutaneously.

(TIF)

S1 Table. Percentage of different peritoneal leukocyte population after immunization and post L3 challenge in all animal groups. Percentages (mean±SE values) of different leukocytes were estimated by flow cytometry after immunization and post L3 challenge in all immunized. Statistical difference between mean values of each cell population post-immunization and post-L3 challenge in each individual group are shown as * P<0.05 and *** P< 0.001. Populations of all cells were increased significantly after L3 challenge in pcD-Myo+Bm-Myo group of mice.

(DOCX)

Acknowledgments
We thank Ms. Shikha Mishra for technical support and Mr. AL Vishwakarma, SAIF, CSIR-CDRI for his assistance in FACS data acquisition. This manuscript bears CDRI communication no. 9104.

Author Contributions
Conceived and designed the experiments: JG SMB. Performed the experiments: JG MP SM. Analyzed the data: JG SMB. Contributed reagents/materials/analysis tools: SMB. Wrote the paper: JG SMB.

References
1. Wolstenholme AJ, Fairweather I, Prichard R, von Samson-Himmelstjerna G, Sangster NC. Drug resistance in veterinary helminths. Trends Parasitol. 2004; 20(10): 469–76. PMID: 15363440
2. Bourguinat C, Pion SD, Kamgno J, Gardon J, Duke BO,Boussinesq M, et al. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl Trop Dis. 2007; 1(1): e72. PMID: 17989786
3. Lustigman S, McCarter JP. Ivermectin resistance in Onchocerca volvulus: toward a genetic basis. PLoS Negl Trop Dis. 2007; 1(1): e76. PMID: 17989789
4. Babu S, Blauvelt CP, Kumaraswami V, Nutman TB. Cutting edge: diminished T cell TLR expression and function modulates the immune response in human filarial infection. J Immunol. 2006; 176(7): 3885–89. PMID: 16547219
5. Anuradha R, George PJ, Kumaran P, Nutman TB, Babu S. Interleukin-10 and transforming growth factor beta-independent regulation of CD8(+) T cells expressing type 1 and type 2 cytokines in human lymphatic filariasis. Clin Vaccine Immunol. 2014; 21(12): 1620–27.
6. Dakshinamoothy G, Samykutty AK, Munirathinam G, Shinde GB, Nutman T, Reddy MV, et al. Biochemical characterization and evaluation of a Brugia malayi small heat shock protein as a vaccine against lymphatic filariasis. PLoS One. 2012; 7(4): e34077. doi: 10.1371/journal.pone.0034077 PMID: 22496777
7. Kushwaha S, Singh PK, Rana AK, Misra-Bhattacharya S. Immunization of Mastomys coucha with Brugia malayi recombinant trehalose-6-phosphate phosphatase results in significant protection against homologous challenge infection. PLoS One. 2013; 8(8): e72585. doi: 10.1371/journal.pone.0072585 PMID: 24015262
8. Veerapathran A, Dakshinamoorothy G, Gnanasekar M, Reddy MV, Katyanasundaram R. Evaluation of Wuchereria bancrofti GST as a vaccine candidate for lymphatic filariasis. PLoS Negl Trop Dis. 2009; 3(6): e457. doi: 10.1371/journal.pntd.0000457 PMID: 19513102

9. Madhumathi J, Prince PR, Anugraha G, Kiran P, Rao DN, Reddy MV, et al. Identification and characterization of nematode specific protective epitopes of Brugia malayi TRX towards development of synthetic vaccine construct for lymphatic filariasis. Vaccine. 2010; 28(31): 5038–48. PMID: 20653106

10. Murray J, Gregory WF, Gomez-Escobar N, Atmadja AK, Maizels RM. Expression and immune recognition of Brugia malayi VAL-1, a homologue of vespid venom allergens and Ancylostoma secreted proteins. Mol Biochem Parasitol. 2001; 118(1): 89–96. PMID: 11704277

11. Pokharel DR, Rai R, Nandakumar Kodumudi K, Reddy MV, Rathaur S. Vaccination with Setaria cervi 175 kDa collagenase induces high level of protection against Brugia malayi infection in jirds. Vaccine. 2006; 24(37–39): 6208–15. PMID: 16870314

12. Nag JK, Shrivastava N, Gupta J, Misra-Bhattacharya S. Recombinant translation initiation factor-1 of Wolbachia is an immunogenic excretory secretory protein that elicits Th2 mediated immune protection against Brugia malayi. Comp Immunol Microbiol Infect Dis. 2013; 36(1): 25–38. doi: 10.1016/j.cimid.2012.09.004 PMID: 23079772

13. Vedi S, Dangi A, Hajela K, Misra-Bhattacharya S. Vaccination with 73kDa recombinant heavy chain myosin generates high level of protection against Brugia malayi challenge in jird and mastomys models. Vaccine. 2008; 26(47): 5997–6005. doi: 10.1016/j.vaccine.2008.06.073 PMID: 18817835

14. Verma SK, Bansal I, Vedi S, Saxena JK, Katoch VM, Bhattacharya SM. Molecular cloning, purification and characterisation of myosin of human lymphatic filarial parasite Brugia malayi. Parasitol Res. 2008; 102(3): 481–89. PMID: 18064491

15. Obwaller A, Duchene M, Bruhn H, Steipe B, Tripp C, Kraft D, et al. Recombinant dissection of myosin heavy chain of Toxocara canis shows strong clustering of antigenic regions. Parasitol Res. 2001; 87(5): 383–89. PMID: 11403381

16. Bennuru S, Semnani R, Meng Z, Ribeiro JM, Veenstra TD, Nutman TB, et al. Brugia malayi excreted/secreted proteins at the host/parasite interface: stage- and gender-specific proteomic profiling. PLoS Negl Trop Dis. 2009; 3(4): e410. doi: 10.1371/journal.pntd.0000410 PMID: 19352421

17. Shrivastava N, Singh PK, Nag JK, Kushwaha S, Misra-Bhattacharya S. Immunization with a multisubunit vaccine considerably reduces establishment of infective larvae in a rodent model of Brugia malayi. Comp Immunol Microbiol Infect Dis. 2013; 36(5): 507–19. doi: 10.1016/j.cimid.2013.05.003 PMID: 23829972

18. Jones S, Evans K, McElwaine-Johnn H, Sharpe M, Oxford J, Lambkin-Williams R, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine. 2009; 27(18): 2506–12. doi: 10.1016/j.vaccine.2009.02.061 PMID: 19368793

19. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, et al. Encapsulated plasmid DNA treatment against Brugia malayi infection in jirds. Vaccine. 2008; 26(31): 3947–57. PMID: 18724414

20. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv Genet. 2005; 55: 25–40. PMID: 16291211

21. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5N1 hemagglutinin. Vaccine. 2010; 28(13): 2565–72. doi: 10.1016/j.vaccine.2010.01.029 PMID: 20117726

22. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008; 26(31): 3947–57. PMID: 18724414

23. Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, McKinney KA, et al. Induction of anti-tumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine. 2009; 27(3): 431–40. doi: 10.1016/j.vaccine.2008.10.078 PMID: 19022315

24. Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 1997; 4(12): 1341–49. PMID: 9472558

25. Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Bamhart K, Nolasco M, et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther. 1996; 7(10): 1205–17. PMID: 8793545

26. Zheng C, Juhasz C, Oswald D, Sack F, Westfehling I, Wittling B, et al. Effect of different nuclear localization sequences on the immune responses induced by a MIDGE vector encoding bovine herpesvirus-1 glycoprotein D. Vaccine. 2006; 24(21): 4625–29. PMID: 16154243
27. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol. 1996; 156(1): 238–45. PMID: 8598468

28. Mellstedt H, Fagerberg J, Frodin JE, Henriksson L, Hjelm-Skoog AL, Liljefors M, et al. Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr Opin Hematol. 1999; 6(3): 169–75. PMID: 10226738

29. Balazs DA, Godbey W. Liposomes for use in gene delivery. J Drug Deliv. 2011; 32 (6): 497.

30. Goyal R, Tripathi SK, Tyagi S, Sharma A, Ram KR, Chowdhuri DK, et al. Linear PEI nanoparticles: efficient pDNA/siRNA carriers in vitro and in vivo. Nanomedicine. 2012; 8(2): 167–75. doi: 10.1016/j.nano.2011.06.001 PMID: 21703995

31. Min J, Qu D, Li C, Song X, Zhao Q, Li XA, et al. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection. PLoS One. 2013; 8(4): e61135. doi: 10.1371/journal.pone.0061135 PMID: 23637790

32. Balazs DA, Godbey W. Liposomes for use in gene delivery. J Drug Deliv. 2011; 32 (6): 497.

33. Harrison RA, Wu Y, Egerton G, Bianco AE. DNA immunisation with Brugia malayi paramyosin in rodents after DNA vaccination. Vaccine. 1999; 18(7–8): 647–55. PMID: 10547424

34. Li BW, Zhang S, Curtis KC, Weil GJ. Immune responses to Brugia malayi paramyosin in rodents after DNA vaccination. Vaccine. 1999; 18(1–2): 76–81. PMID: 10501237

35. Catmul J, Wilson ME, Kirchhoff LV, Metwali A, Donelson JE. Induction of specific cell-mediated immunity in mice by oral immunization with Salmonella expressing Onchocerca volvulus glutathione S-transferase. Vaccine. 1999; 17(1): 31–39. PMID: 10078605

36. Ramachandran S, Kumar MP, Rami RM, Chinnaiah HB, Nutman T, Kaliraj P, et al. The larval specific lymphatic filarial ALT-2: induction of protection using protein or DNA vaccination. Microbiol Immunol. 2004; 48(12): 945–55. PMID: 15611611

37. Kushwaha S, Singh PK, Gupta J, Soni VK, Misra-Bhattacharya S. Recombinant trehalose-6-phosphate phosphatase of Brugia malayi cross-reacts with human Wuchereria bancrofti immune sera and engenders a robust protective outcome in mice. Microbes Infect. 2012; 14(14): 1330–39. doi: 10.1016/j.micinf.2012.08.006 PMID: 22981601

38. Kushwaha S, Soni VK, Singh PK, Bano N, Kumar A, Sangwan RS, et al. Withania somnifera chelates NMITLI 101R, NMITLI 118R, NMITLI 128R and withaferin A protect Mastomys couchafrom Brugia malayi infection. Parasite Immunol. 2012; 34(4): 199–209. doi: 10.1111/j.1365-3024.2012.01352.x PMID: 22394222

39. Li L., Saade F., Petrovsky N.. The future of human DNA vaccines. Journal of Biotechnology. 2012; 162 (2):171–82.

40. Nolan T, Izurieta P, Lee BW, Chan PC, Marshall H, Booy R, et al. Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age. J Infect Dis. 2014; 210(11):1800–10 doi: 10.1093/infdis/jiu359 PMID: 24973461

41. Gil A., Shen S., Coley S. et al. DNA vaccine prime followed by live attenuated virus significantly improves antigen specific T cell responses against human cytomegalovirus. Hum Vacc Immunotherap. 2013; 9(10): 2120–32.

42. Mazumder S, Maji M, Das A, Ali N. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. PLoS One. 2011; 6(2): e14644 doi: 10.1371/journal.pone.0014644 PMID: 21311597

43. Cao S, Mousa AA, Aboge GO, et al. Prime-boost vaccination with plasmid DNA followed by recombinant vaccinia virus expressing BgGARP induced a partial protective immunity to inhibit Babesia gibsoni proliferation in dogs. Acta Parasitologica. 2013; 58(4): 619–623. doi: 10.2478/s11686-013-0183-1 PMID: 24338330

44. De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, et al. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLoS One. 2014; 9(2): e87837. doi: 10.1371/journal.pone.0087837 PMID: 24503579

45. Ramshaw I A, Ramsay A J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today. 2000; 21(4):163–65. PMID: 10740236
46. Li YH, Huang S, Du M, Bian Z, Chen Z, Fan MW. Immunogenic characterization and protection against Streptococcus mutans infection induced by intranasal DNA prime–protein boost immunization. Vaccine. 2010; 28(32): 5370–76 doi: 10.1016/j.vaccine.2010.04.067 PMID: 20573581

47. Law M, Cardoso RM, Wilson IA, Burton DR. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime–protein boost immunization strategy. J Virol. 2007; 81(8): 4272–85. PMID: 17267498

48. Davtyan H, Mkrtichyan M, Movsesyan N, Petrushina I, Mamikonyan G, Cribbs DH, et al. DNA prime–protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther. 2010; 17(2): 261–71. doi: 10.1038/gt.2009.140 PMID: 19865176

49. Babayan SA, Attout T, Harris A, Taylor MD, Le Goff L, Vuong PN, et al. Vaccination against filarial nematodes with irradiated larvae provides long-term protection against the third larval stage but not against subsequent life cycle stages. Int J Parasitol. 2006; 36(8): 903–14. PMID: 16765354

50. Babu S, Ganley LM, Klei TR, Shultz LD, Rajan TV. Role of gamma interferon and interleukin-4 in host defense against the human filarial parasite Brugia malayi. Infect Immun. 2000; 68(5): 3034–35. PMID: 10769010

51. Dakshinamoorthy G, Samykutty AK, Munirathinam G, Reddy MV, Kalyanasundaram R. Multivalent fusion protein vaccine for lymphatic filariasis. Vaccine. 2013; 31(12): 1616–22. doi: 10.1016/j.vaccine.2012.09.055 PMID: 23036503

52. Thirugnanam S, Pandiaraja P, Ramaswamy K, Murugan V, Gnanasekar M, Nandakumar K, et al. Brugia malayi: comparison of protective immune responses induced by Bm-alt-2 DNA, recombinant Bm-ALT-2 protein and prime-boost vaccine regimens in a jird model. Exp Parasitol. 2007; 116(4): 483–91. PMID: 17442307

53. Pertmer TM, Roberts TR, Haynes JR. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol. 1996; 70(9): 6119–25.

54. Sahu BR, Mohanty MC, Sahoo PK, Satapathy AK, Ravindran B. Protective immunity in human filariasis: a role for parasite-specific IgA responses. J Infect Dis. 2008; 198(3): 434–43. doi: 10.1086/589881 PMID: 18588480

55. Ramalingam T, Rajan B, Lee J, Rajan T V. Kinetics of Cellular Responses to Intraperitoneal Brugia pahangi Infections in Normal and immunodeficient Mice. Infection and immunity.2003; 71(8): 4361–67. PMID: 12674313

56. Ramesh M., Paciorkowski N., Dash Y., Shultz L., Rajan T. V. Acute but not chronic macrophage recruitment in filarial infections in mice is dependent on C-C chemokine ligand 2. Parasite Immunology. 2007; 29, 29: 395–404. PMID: 17650181

57. Gallo A M, Hess J A, Nolan T J, Schad G A. Role of Eosinophils and Neutrophils in Innate and Adaptive Protective Immunity to Larval Strongyloides stercoralis in Mice. Infection and immunity.2006; 74 (10): 5730–5738. PMID: 16988250

58. Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol. 2000; 30(4): 985–92. PMID: 10760785

59. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NK cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol. 2000; 12(7): 987–94 PMID: 10882410